Annual report pursuant to Section 13 and 15(d)

Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)

v3.22.4
Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
May 31, 2020
USD ($)
Dec. 31, 2022
USD ($)
Faculty
Dec. 31, 2021
USD ($)
Oct. 07, 2022
USD ($)
Collaborations, Licensing Agreements And Other Agreements [Line Items]        
Research and development expense   $ 39,300 $ 32,494  
License Agreement        
Collaborations, Licensing Agreements And Other Agreements [Line Items]        
Obligation to be paid   $ 2,000    
Payment term   3 years    
Payment commencement date   2018-08    
License maintenance fee $ 33 $ 10    
Total milestone payments   21,000    
Amounts due to agreement   0 0  
Sponsored Research Agreements | Penn        
Collaborations, Licensing Agreements And Other Agreements [Line Items]        
Obligation to be paid   $ 12,560    
Number of faculty member | Faculty   2    
Funding term end date   2022-11    
Research and development expense   $ 2,624 2,840  
Sponsored Research Agreements | Penn | Accrued and Other Current Liabilities        
Collaborations, Licensing Agreements And Other Agreements [Line Items]        
Obligation to be paid   77 36  
Master Translational Research Services Agreement        
Collaborations, Licensing Agreements And Other Agreements [Line Items]        
Research and development expense   2,623 1,933  
Remaining research and development expense to be incurred   1,100    
Oxford Biomedica        
Collaborations, Licensing Agreements And Other Agreements [Line Items]        
Obligation to be paid     $ 4,000  
Research and development expense   1,100    
IASO Biotherapeutics        
Collaborations, Licensing Agreements And Other Agreements [Line Items]        
upfront license fee   $ 162,000   $ 2,500